- Home
- PCSA vs EDUC Comparison
PCSA vs EDUC Comparison
Compare PCSA & EDUC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCSA
- EDUC
- Stock Information
- Founded
- PCSA 2011
- EDUC 1965
- Country
- PCSA United States
- EDUC United States
- Employees
- PCSA N/A
- EDUC N/A
- Industry
- PCSA Biotechnology: Pharmaceutical Preparations
- EDUC Consumer Specialties
- Sector
- PCSA Health Care
- EDUC Consumer Discretionary
- Exchange
- PCSA Nasdaq
- EDUC Nasdaq
- Market Cap
- PCSA 12.0M
- EDUC 13.4M
- IPO Year
- PCSA N/A
- EDUC N/A
- Fundamental
- Price
- PCSA $0.27
- EDUC $1.26
- Analyst Decision
- PCSA Strong Buy
- EDUC
- Analyst Count
- PCSA 1
- EDUC 0
- Target Price
- PCSA $1.00
- EDUC N/A
- AVG Volume (30 Days)
- PCSA 4.4M
- EDUC 742.6K
- Earning Date
- PCSA 11-06-2025
- EDUC 10-09-2025
- Dividend Yield
- PCSA N/A
- EDUC N/A
- EPS Growth
- PCSA N/A
- EDUC N/A
- EPS
- PCSA N/A
- EDUC N/A
- Revenue
- PCSA N/A
- EDUC $29,415,900.00
- Revenue This Year
- PCSA N/A
- EDUC N/A
- Revenue Next Year
- PCSA N/A
- EDUC N/A
- P/E Ratio
- PCSA N/A
- EDUC N/A
- Revenue Growth
- PCSA N/A
- EDUC N/A
- 52 Week Low
- PCSA $0.15
- EDUC $0.92
- 52 Week High
- PCSA $1.50
- EDUC $2.00
- Technical
- Relative Strength Index (RSI)
- PCSA 43.44
- EDUC 39.03
- Support Level
- PCSA $0.29
- EDUC $1.29
- Resistance Level
- PCSA $0.35
- EDUC $1.42
- Average True Range (ATR)
- PCSA 0.05
- EDUC 0.12
- MACD
- PCSA -0.01
- EDUC -0.02
- Stochastic Oscillator
- PCSA 3.69
- EDUC 4.17
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
About EDUC Educational Development Corporation
Educational Development Corp is the United States trade publisher of the line of educational children's books produced in the United Kingdom. Its business activity functions with two reportable segments: PaperPie and Publishing. The Publishing Division segment markets its products to retail accounts, which include books, school supplies, toy and gift stores and museums, through commissioned sales representatives, trade and specialty wholesalers and an internal telesales group.